Trial | NCT01781702  Report issue

Title

Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients
A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    120
A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients
Study Started
Oct 31
2010
Primary Completion
Oct 31
2011
Study Completion
Oct 31
2011
Last Update
Aug 09
2013
Estimate

Drug Pelubiprofen 30 mg

Drug Celebrex 200 mg

Pelubiprofen 30 mg Experimental

Pelubiprofen 30 mg, tid

Celebrex 200 mg Active Comparator

Celebrex 200 mg, tid

Criteria 

Inclusion Criteria:

Adult males/Females aged 18~80 years
Patient who are taking NSAIDs for the treatment of rheumatoid arthritis
Patients who belong to ACR functional class 1, 2, 3

Exclusion Criteria:

Patients who belong to ACR functional class 4
Patients who are hypersensitive to clinical trial medicines or excipient
Patients who have experience of Cerebrovascular bleeding, bleeding disorder
No Results Posted